We noticed you are on our UK page. Want to switch regions? Choose from the options:

dr-wasiru-saka
/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_Medical_Oncologist_Headshot_GA_Dr-Wasiru-Saka.jpg

Dr Wasiru Saka

Dr Wasiru Saka
MBChB, MRCP, MRCP
Medical Oncologist

Languages spoken

English

Expert in

Upper GI cancers and lower GI cancers

Overview

Centres

Milton Keynes
Milton Keynes

GenesisCare, Sunrise Parkway, Linford Wood, East, Milton Keynes MK14 6LS, UK

52.05838, -0.76101
/uk/our-centres/milton-keynes

Specialises in

Gastrointestinal cancer
Condition
Condition/Cancer
Condition/Cancer/Gastrointestinal cancer

Treatments

Chemotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Chemotherapy
Immunotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Immunotherapy

He has special clinical interest in upper GI cancers, lower GI cancers, HPB cancers and melanomas.

Dr Saka is a Consultant medical oncologist at MKUH since 2015 with special interest in upper and lower GI cancers. He is the lead for Carcinoma of unknown primary and Acute Oncology. He is a conscientious oncologist with a focus on providing the best outcomes for his patients and involving them in all decision making. He provides private practice at GenesisCare in Milton Keynes which provides complimentary exercise medicine and complimentary therapies as part of their private care.

He is also heavily involved in research to look at improving patient outcomes and provides teaching and supervision to medical students as part of his role.

Career positions

Current position(s)

  • Medical Oncologist

Education

Universities

  • Milton Keynes University Hospital

Residencies

  • Milton Keynes University Hospital

 

Expertise and interests

Expertise

Interests

  • Upper GI cancers
  • Lower GI cancers
  • Gastrointestinal Cancers
  • Neoadjuvant chemotherapy
  • Metastic Cancer
  • Colorectal cancer with liver metastases

Professional association

  • General Medical Council (GMC)

Accomplishments

Publications

  • Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen (June 2018)